Lead pharma rivals in drug access for poor
- Mercedes hit-and-run case: Delhi teenager charged with culpable homicide
- Vijay Mallya skips ED for the third time, seeks time till May
- PM Modi asks for first report on Panama Papers revelations in 15 days
- Opinion: The IPL water controversy proves that common sense is least common
- From well near Wankhede stadium, goes water for IPL — and a thirsty city
Drugmakers - led by GlaxoSmithKline and Johnson & Johnson - are stepping up efforts to ensure their medicines are available and affordable in poor countries, after being attacked in the past for not doing enough.
The Access to Medicines Index, which tracks the actions of the top 20 drugmakers, showed on Wednesday there had been an improvement across the board in the past two years, reflecting both commercial self-interest and a concern for reputation.
Still, the nonprofit group behind the index took companies to task for not being more open about the widespread outsourcing of clinical trials in overseas countries, where many studies are handled by contract research organisations (CROs).
The analysis found no company was fully transparent about all the CROs it used, and only four - Merck & Co, Sanofi , GlaxoSmithKline and Eisai - provided evidence of enforcing codes of conduct to ensure CRO trials met safety and ethical standards.
Companies are increasingly conducting clinical trials in eastern Europe, Asia and Latin America, where costs are often lower and patients easier to recruit.
Low cost, High voume
With emerging markets now a top priority for pharmaceutical companies worldwide, as sales in Western nations slow, firms are experimenting with a wide variety of low-cost, high-volume models to boost business.
As a result, Wim Leereveld, founder of the Amsterdam-based Access to Medicine Foundation, said companies were becoming much more organised internally in addressing the needs of low-income markets.
More companies are now adopting tiered pricing, with prices in poor countries sometimes reduced by 50 to 75 percent, although this varies considerably between companies, products and markets.
Britain's GlaxoSmithKline came top in the 2012 index, based on an assessment of performance across a range of activities, such as drug donation, patent policy, pricing and research.
Johnson & Johnson was second and Sanofi third, while Japanese drugmakers came bottom of the table.
- India needs to rationalise capital controls, simplify its tax regime
- Talks must continue to be resilient against disruptions in the normalisation process
- No proof required: Fadnavis everywhere, and no water to drink
- For the first time procurement has been linked to production
- Pakistan has long suffered from this delusion which keeps the state from serving its citizens
- Angry populism against corrupt elites could grow. But in India, reaction will be muted